register free | resend password

Pressemitteilungen zu dem Thema emd


Unterkategorien

PresseMitteilungen zu dem Schlagwort emd


InspireMD Schedules Third Quarter 2017 Earnings Conference Call

TEL AVIV, ISRAEL -- (Marketwired) -- 11/01/17 -- (NYSE American: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that it will host a conference call on Wednesday, November 8th at 8:00 a.m. Eastern Time to discuss the company''s financial results for the third quarter ended September 30, 2017, as well as the Company''s corporate progress and other meaningful developments.The conference call wil ...


01.11.2017

InspireMD''s CGuard(TM) Carotid Embolic Prevention System Featured in Live Case at Cracow Vascular Summit 2017 in Poland

TEL AVIV, ISRAEL -- (Marketwired) -- 10/25/17 -- (NYSE MKT: NSPR) (NYSE MKT: NSPR.WS) (NYSE American: NSPR) (NYSE American: NSPR.WS), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that Prof. Waclaw Kuczmik, Head of the Vascular Surgery Department of Katowice Clinical Hospital N 7 and his team, performed a live endovascular interventional procedure featuring the CGuard™ EPS at the 4th Edition of the Cracow Vascular Sum ...


25.10.2017

New York Stock Exchange Accepts InspireMD''s Plan to Regain Compliance

TEL AVIV, ISRAEL -- (Marketwired) -- 10/24/17 -- (NYSE AMER: NSPR) (NYSE AMER: NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that the New York Stock Exchange has accepted the Company''s plan to regain compliance with the NYSE American''s stockholder''s equity continued listing standard (Part 10, Section 1003(a)(iii)). As previou ...


24.10.2017

InspireMD Announces Distribution Agreement for MGuard Prime(TM) in Chile

TEL AVIV, ISRAEL -- (Marketwired) -- 10/12/17 -- (NYSE American: NSPR) (NYSE MKT: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it has signed an agreement with CorpMedical Chile Ltda, a leading medical distributor in Chile, with its headquarters in Santiago de Chile, to distribute the MGuard Prime™ Embolic Protection System (EPS) for the treatment of acute coronary syndromes, namely Acute Myocardial Infarctions ...


12.10.2017

InspireMD Announces the Start of Patient Enrollment in an Investigator Initiated Trial of CGuard(TM) EPS in Russia

TEL AVIV, ISRAEL -- (Marketwired) -- 10/09/17 -- (NYSE American: NSPR) (NYSE MKT: NSPR), a leader in Embolic Prevention Systems (EPS) / thrombus management technologies and neurovascular devices, today announced the start of patient enrollment in an investigator initiated trial in Russia, entitled: Independent Randomized Trial in Carotid Artery Revascularization Comparing the Stent (Acculink™) Versus CGuard™EPS. The objective of the trial is to assess the neuro protection and clinical superior ...


09.10.2017

InspireMD Postpones Special Meeting of Stockholders to October 27, 2017

TEL AVIV, ISRAEL -- (Marketwired) -- 10/04/17 -- (NYSE MKT: NSPR) (NYSE American: NSPR) (NYSE MKT: NSPR.WS) (NYSE American: NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that it has postponed its Special Meeting of Stockholders that was to have taken place originally on October 3, 2017. The new date for the Special Meeting is October 27, 2017 at 11:30 a.m. E ...


04.10.2017

InspireMD Announces Distribution Agreement for CGuard(TM) EPS in Portugal

TEL AVIV, ISRAEL -- (Marketwired) -- 09/21/17 -- (NYSE MKT: NSPR) (NYSE American: NSPR) (NYSE MKT: NSPR.WS) (NYSE American: NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it has signed an agreement with Medicinália Cormédica MC Medical Lda, a leading medical distributor in Portugal, to distribute CGuard™ EPS (Embolic Prevention System). Medicinália Cormédica ...


21.09.2017

InspireMD to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City

TEL AVIV, ISRAEL -- (Marketwired) -- 09/06/17 -- (NYSE American: NSPR) (NYSE American: NSPR.WS) (NYSE MKT: NSPR) (NYSE MKT: NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it will present at the 19th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 10-12, 2017 at Lo ...


06.09.2017

InspireMD Announces Distribution Agreement for CGuard(TM) EPS in Switzerland

TEL AVIV, ISRAEL -- (Marketwired) -- 08/25/17 -- (NYSE American: NSPR) (NYSE American: NSPR.WS) (NYSE MKT: NSPR) (NYSE MKT: NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it has signed an agreement with 1a medical ag, a leading medical distributor in Switzerland, to distribute CGuard™ EPS (Embolic Prevention System).Agustin Gago, EVP and Chief Commercial Offi ...


25.08.2017

InspireMD Shares CGuard(TM) EPS Video Testimonials from European Key Opinion Leaders

TEL AVIV, ISRAEL -- (Marketwired) -- 08/22/17 -- (NYSE American: NSPR) (NYSE MKT: NSPR) (NYSE American: NSPR.WS) (NYSE MKT: NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it has posted video testimonials about its CGuard™ Embolic Prevention System from several European key opinion leaders on its website:Featured testimonials include:Dr. Alberto Cremonesi, Chi ...


22.08.2017

InspireMD Announces Notification of NYSE AMERICAN Listing Deficiency and Expectation to Regain Compliance

TEL AVIV, ISRAEL -- (Marketwired) -- 08/22/17 -- (NYSE American: NSPR) (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it received a letter from the NYSE American on August 17, 2017 indicating that InspireMD does not meet a certain NYSE American LLC (the "NYSE American") continued listing standard as set forth in Part 10, Section 1003(a)(iii) ...


22.08.2017

InspireMD Announces Publication of an Independent Clinical Review Authored by Leading U.S. and European Physicians Supporting Safety Advantages of Mesh-Covered Carotid Stents

TEL AVIV, ISRAEL -- (Marketwired) -- 08/07/17 -- (NYSE American: NSPR) (NYSE MKT: NSPR) (NYSE American: NSPR.WS) (NYSE MKT: NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced the publication of the independent study entitled, "One swallow does not a summer make but many swallows do: accumulating clinical evidence for nearly-eliminated peri-procedural and 30- ...


07.08.2017

InspireMD''s CGuard Carotid Embolic Prevention System Featured at the SOLACI CACI Congress of Cardiology 2017 in Buenos Aires

TEL AVIV, ISRAEL -- (Marketwired) -- 08/03/17 -- (NYSE MKT: NSPR) (NYSE MKT: NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that an endovascular interventional procedure featuring the CGuard™ EPS performed by the team of Dr. Anibal Damonte, Interventional Cardiologist, Director of Interventional Cardiology at the Cardiovascular Institute of Rosario, and Vice ...


03.08.2017

InspireMD Schedules Second Quarter 2017 Earnings Conference Call

TEL AVIV, ISRAEL -- (Marketwired) -- 08/02/17 -- (NYSE MKT: NSPR) (NYSE MKT: NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that it will host a conference call on Wednesday, August 9th at 8:00 a.m. Eastern Time to discuss the company''s financial results for the second quarter ended June 30, 2017, as well as the Company''s corporate progre ...


02.08.2017

InspireMD Announces Completion of Transition from Exclusive European Distributor to InspireMD Managed Local Distribution Network

TEL AVIV, ISRAEL -- (Marketwired) -- 06/13/17 -- (NYSE MKT: NSPR) (NYSE MKT: NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it has signed distribution agreements for CGuard™ EPS with Comesa GmbH, as well as "be medical," who are among the leading medical distributors in Austria and Belgium, respectively. Consequently, all territories previously cove ...


13.06.2017

InspireMD to Present at the 2017 Marcum Microcap Conference

TEL AVIV, ISRAEL -- (Marketwired) -- 06/09/17 -- InspireMD, Inc. (NYSE MKT: NSPR) (NYSE MKT: NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it will be presenting at the on Friday, June 16th at 10:30 AM EST. James Barry, PhD, Chief Executive Officer of InspireMD will be presenting and meeting with investors.The Marcum MicroCap Conference () is a nationally rec ...


09.06.2017

InspireMD Announces Distribution Agreement for CGuard EPS in Taiwan

TEL AVIV, ISRAEL -- (Marketwired) -- 06/08/17 -- (NYSE MKT: NSPR) (NYSE MKT: NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it has signed an agreement with LORION Enterprises Inc., a leading medical distributor in Taiwan, to distribute CGuard™ EPS (Embolic Prevention System).Agustin Gago, EVP and Chief Commercial Officer of InspireMD, commented, "In line ...


08.06.2017

InspireMD Announces the Publication of an Investigator Initiated Clinical Registry Reaffirming MGuard(TM) Prime as a Highly Effective Tool to Prevent Heart Damage in Coronary Artery Blockages with High Thrombotic Content

TEL AVIV, ISRAEL -- (Marketwired) -- 06/07/17 -- (NYSE MKT: NSPR) (NYSE MKT: NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced the publication of an independent clinical study entitled, "Long term Outcomes of MGuard™ Stent Deployment in Saphenous Vein Grafts and Native Coronary Arteries: A Single Center Experience," in the Israel Medical Association Jo ...


07.06.2017

InspireMD Announces Distribution Agreement for CGuard(TM) EPS in Poland

TEL AVIV, ISRAEL -- (Marketwired) -- 06/05/17 -- (NYSE MKT: NSPR) (NYSE MKT: NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it has signed an agreement with Arteriae Sp. z o.o. sp.k, a leading medical distributor in Poland, to distribute CGuard™ EPS (Embolic Prevention System).Agustin Gago, EVP and Chief Commercial Officer of InspireMD, commented, "We are ...


05.06.2017

InspireMD Announces Appointment of Paul Stuka as Chairman of the Board

TEL AVIV, ISRAEL -- (Marketwired) -- 06/02/17 -- (NYSE MKT: NSPR) (NYSE MKT: NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that Paul Stuka, who has served on the Company''s Board of Directors since 2011, has been appointed Chairman of the Board, replacing Sol Barer, Ph.D., who is stepping down from the Board due to conflicting professional commitme ...


02.06.2017

InspireMD Announces First Two Patients in Hong Kong Successfully Treated with CGuard EPS

TEL AVIV, ISRAEL -- (Marketwired) -- 05/30/17 -- (NYSE MKT: NSPR) (NYSE MKT: NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced the first two patients in Hong Kong have been successfully treated with CGuard™ EPS. The two cases were conducted on patients with carotid artery stenosis at St. Teresa Hospital by Dr. PW Cheng and Dr. YW Chow, a leading neurointerventio ...


30.05.2017

2018 SEMDA Annual Conference Will be Held in Greenville, SC

ATLANTA, GA -- (Marketwired) -- 12/21/16 -- The (SEMDA) is pleased to announce that the 2018 Conference will be held in Greenville, South Carolina. The 12th annual conference will take place May 1-3, 2018, at the Hyatt Regency in downtown Greenville."The South Carolina medtech industry has been a strong supporter of SEMDA for many years and is growing at one of the fastest rates in the country," said Jason Rupp, Executive Director of SEMDA. "From 2012-2014, the number of new med ...


21.12.2016

InspireMD to Present at LD Micro Main Event on December 6

BOSTON, MA -- (Marketwired) -- 11/28/16 -- (NYSE MKT: NSPR) (NYSE MKT: NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced that Chief Financial Officer Craig Shore will present at the LD Micro 9th Annual Main Event on Tuesday, December 6, 2016 at 7:30 a.m. PT in Los Angeles, California. Mr. Shore will provide a corporate overview and discuss the Company'' ...


28.11.2016

InspireMD Announces CGuard(TM) Embolic Prevention System Commercialization Approval in Russia

BOSTON, MA -- (Marketwired) -- 11/14/16 -- InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced that it has received regulatory approval to commercialize the CGuard™ Embolic Prevention System for the treatment of carotid artery disease in Russia. The approval was granted by Russia''s Federal Service for Surveillance in Healthcare (Ro ...


14.11.2016

InspireMD to Report Third Quarter Financial Results on Monday, November 14, 2016

BOSTON, MA -- (Marketwired) -- 11/07/16 -- (NYSE MKT: NSPR.WS), a leader in embolic protection systems, announced today that it will release its financial results for the third quarter ended September 30, 2016 on Monday, November 14 after the market close, followed by a conference call at 4:30 p.m. ET to review results and provide a company update.Participants should call 866-652-5200 (United States) or 412-317-6060 (International) and request the InspireMD call. A live webcast will be availab ...


07.11.2016

InspireMD CGuard(TM) Embolic Prevention System 12-Month Clinical Trial Data Further Validate Potential of CGuard(TM) to Improve Management of Carotid Artery Disease and Prevent Stroke

BOSTON, MA -- (Marketwired) -- 11/01/16 -- (NYSE MKT: NSPR) (NYSE MKT: NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced 12-month follow up data from PARADIGM-101 of the CGuard™ Embolic Prevention System (EPS) which were presented in two presentations at the Transcatheter Cardiovascular Therapeutics (TCT) 2016 scientific symposium, taking place October 29 - Novem ...


01.11.2016

Long-term Clinical Data on InspireMD''s CGuard Embolic Prevention System to be Presented at Transcatheter Cardiovascular Therapeutics (TCT) Scientific Symposium

BOSTON, MA -- (Marketwired) -- 10/27/16 -- (NYSE MKT: NSPR) (NYSE MKT: NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced that 12-month follow up data from PARADIGM-101, an investigator led clinical trial evaluating the Company''s CGuard™ Embolic Prevention System (EPS), will be discussed in two presentations at the Transcatheter Cardiovascular Therapeut ...


27.10.2016

InspireMD Announces Appointment of Medical Device Industry Veteran Agustin Gago as Chief Commercial Officer

BOSTON, MA -- (Marketwired) -- 10/26/16 -- (NYSE MKT: NSPR) (NYSE MKT: NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced the appointment of Agustin Gago as the Company''s Executive Vice President and Chief Commercial Officer. In this role, Mr. Gago will be responsible for developing and implementing InspireMD''s global sales, distribution and ...


26.10.2016

InspireMD Announces Independent Study Published in the Journal of Endovascular Therapy That Continues to Support the Clinical Benefit and Utility of the CGuard Embolic Prevention System

BOSTON, MA -- (Marketwired) -- 10/17/16 -- (NYSE MKT: NSPR) (NYSE MKT: NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced the online publication of positive clinical data in a new independent study performed by Prof. Christian Wissgott, M.D., entitled "Clinical Results and Mechanical Properties of the Carotid CGuard™ Double-Layered Embolic Prevention Stent,&q ...


17.10.2016

InspireMD to Present at the Dawson James Securities 2nd Annual Growth Stock Conference on October 20

BOSTON, MA -- (Marketwired) -- 10/13/16 -- (NYSE MKT: NSPR) (NYSE MKT: NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced that President and Chief Executive Officer James Barry, PhD will present at the Dawson James Securities 2nd Annual Growth Stock Conference on Thursday, October 20, 2016 at 12:15 p.m. ET in Jupiter, Florida. Dr. Barry will provide a corporate ov ...


13.10.2016

InspireMD Announces Adjustments to Shares Receivable Upon Warrant Exercise and Exercise Price per Share

BOSTON, MA -- (Marketwired) -- 10/06/16 -- (NYSE MKT: NSPR) (NYSE MKT: NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced that in conjunction with the 1-for-25 reverse stock split announced last week following the Company''s special meeting of stockholders, the number of shares of common stock of InspireMD receivable upon exercise of one warrant currentl ...


06.10.2016

InspireMD Appoints Thomas Kester to Board of Directors

BOSTON, MA -- (Marketwired) -- 09/07/16 -- (NYSE MKT: NSPR) (NYSE MKT: NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced the appointment of Thomas Kester to the Company''s Board of Directors and Chairman of the Company''s Audit Committee. Mr. Kester brings over 40 years of public accounting experience as well as Board member experience with pu ...


07.09.2016

InspireMD to Report Second Quarter Financial Results on Tuesday, August 9, 2016

BOSTON, MA -- (Marketwired) -- 08/02/16 -- (NYSE MKT: NSPR) (NYSE MKT: NSPR.WS), a leader in embolic protection systems, announced today that it will release its financial results for the second quarter ended June 30, 2016 on Tuesday, August 9 after the market close, followed by a conference call at 4:30 p.m. ET to review results and provide a company update.Participants should call (866) 652-5200 (United States) or (412) 317-6060 (International) and request the InspireMD call. A live webcast ...


02.08.2016

UPDATE - InspireMD Announces Listing of Warrants on the NYSE MKT

BOSTON, MA -- (Marketwired) -- 08/01/16 -- (NYSE MKT: NSPR) (NYSE MKT: NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic protection systems (EPS), neurovascular devices and thrombus management technologies, today announced the listing of the Company''s 44,242,424 previously issued warrants on the NYSE MKT (the "Exchange"). Beginning at the market open on August 1, 2016, the warrants will commence trading under the ticker symbol "NSPR.WS.& ...


01.08.2016

InspireMD Announces Listing of Warrants on the NYSE MKT

BOSTON, MA -- (Marketwired) -- 08/01/16 -- (NYSE MKT: NSPR, ) ("InspireMD" or the "Company"), a leader in embolic protection systems (EPS), neurovascular devices and thrombus management technologies, today announced the listing of the Company''s 44,242,424 previously issued warrants on the NYSE MKT (the "Exchange"). Beginning at the market open on August 1, 2016, the warrants will commence trading under the ticker symbol "NSPR.WS."On July 7, 20 ...


01.08.2016

CORRECTION - InspireMD Announces Pricing of Public Offering of Approximately $14.6 Million

BOSTON, MA -- (Marketwired) -- 06/30/16 -- In the news release, "InspireMD Announces Pricing of Public Offering of Approximately $14.6 Million," issued earlier today by InspireMD, Inc. (NYSE MKT: NSPR), we are advised by the company that in the first sentence of the first paragraph, it should read "44,242,424 shares" rather than "44,242,424 million shares" as originally issued. Complete corrected text follows.BOSTON, MA -- June 30, 2016 -- (NYSE MKT: NSPR) (" ...


01.07.2016

InspireMD Announces Pricing of Public Offering of Approximately $14.6 Million

BOSTON, MA -- (Marketwired) -- 06/30/16 -- (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced the pricing of a "best efforts" public offering of approximately 442,424 shares of Series B Convertible Preferred Stock and accompanying warrants to purchase up to approximately 44,242,424 million shares of common stock. Each share of Series B Convertibl ...


30.06.2016

InspireMD Announces Amendment to Loan & Security Agreement With Hercules Capital

BOSTON, MA -- (Marketwired) -- 06/14/16 -- (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced that it has completed a restructuring of its existing debt.The Company restructured its term loan with lenders and Hercules Capital ("Hercules" or "Lenders"), which has an outstanding balance of approximately $3.6 million, effective immediately ...


14.06.2016

InspireMD Names Dr. James Barry as President and CEO

BOSTON, MA -- (Marketwired) -- 06/07/16 -- (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced the appointment of James Barry, Ph.D. as President and CEO effective immediately. Prior to this appointment, Dr. Barry served as InspireMD''s Chief Operating Officer since July 2014 and has been a member of the Company''s Board of Directors sin ...


07.06.2016

SEMDA Launches Medtech Women @ SEMDA

ATLANTA, GA -- (Marketwired) -- 05/24/16 -- The (SEMDA) is pleased to announce the launch of Medtech Women @ SEMDA, a group within the organization dedicated to enhancing opportunities for women in the medtech industry.Tiffany Wilson, Executive Director of the Global Center for Medical Innovation, a SEMDA Board Member, and the Chair of Medtech Women @ SEMDA, laid out the vision of the group: "Our vision is to serve as a strong advisory network for mentoring and professional development fo ...


24.05.2016

InspireMD''s CGuard(TM) Highlighted at the Late-Breaking Clinical Trial Session at the EuroPCR 2016 Conference

BOSTON, MA -- (Marketwired) -- 05/17/16 -- (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced that CGuard™ EPS reported positive results in PARADIGM-101, an investigator led clinical evaluation of the system for routine use in 101 consecutive, increased risk patients undergoing carotid artery stenting. Principle investigator Prof. Piotr Musialek presented ...


17.05.2016

NFANT Labs Expanding Connected Neonatal Product Line With Upcoming Series B Offering

ATLANTA, GA -- (Marketwired) -- 05/17/16 -- will kick off their Series B round of financing at the 10th annual Southeastern Medical Device Association (SEMDA) Conference to be held on May 18-19 in Nashville, Tennessee. The presentation will mark the third time NFANT will kick off financing efforts at SEMDA, having completed a $125K Seed and Series A round totaling $2.5M over the past two years. The upcoming Series B financing is anticipated to be $5M and will continue NFANT Labs'' ef ...


17.05.2016

InspireMD Reports Financial Results for the First Quarter Ended March 31, 2016

BOSTON, MA -- (Marketwired) -- 05/10/16 -- (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced its financial and operating results for the first quarter ended March 31, 2016.During the first quarter, InspireMD announced initiatives to support ongoing commercial operations and development programs. Key activities include announced:Completed private placement ...


10.05.2016

InspireMD Announces Late-Breaking Trial Presentation on CGuard(TM) Embolic Prevention System at EuroPCR 2016 Conference

BOSTON, MA -- (Marketwired) -- 05/05/16 -- (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced that CGuard™ EPS will be featured at the Late-Breaking Trial presentation at the upcoming EuroPCR conference from May 17-20, 2016 in Paris, France.A leading course in interventional cardiovascular medicine, EuroPCR hosts over 120 companies from the industry, inclu ...


05.05.2016

UPDATE: InspireMD Receives Audit Opinion With Going Concern Explanation

BOSTON, MA -- (Marketwired) -- 03/31/16 -- (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced that as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2015, which was filed on March 28, 2016 with the Securities and Exchange Commission, the audited financial statements contained a going concern qualification paragraph i ...


31.03.2016

InspireMD Receives Audit Opinion With Going Concern Explanation

BOSTON, MA -- (Marketwired) -- 03/31/16 -- (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced that as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2015, which was filed on March 28, 2016 with the Securities and Exchange Commission, the audited financial statements contained a going concern qualification paragraph i ...


31.03.2016

InspireMD Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2015

BOSTON, MA -- (Marketwired) -- 03/28/16 -- (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced its financial and operating results for the fourth quarter and year ended December 31, 2015.In 2015, InspireMD advanced its strategic transition into the carotid and neuro interventional markets utilizing its proprietary MicroNet™ technology. Key activities includ ...


28.03.2016

iNeedMD Signs Share Exchange Agreement to Acquire US Master Distributor Mediplex Alliances and Agrees to Appoint Jonathan Loutzenhiser as President

NEW YORK, NY -- (Marketwired) -- 03/22/16 -- iNeedMD Holdings, Inc. (OTCQB: NEMD) ("iNeedMD" or the "Company") a medical device developer, is pleased to announce the Company''s strategic acquisition of Mediplex Alliances Inc., a Delaware corporation ("Mediplex") and the appointment of Jonathan Loutzenhiser as President of iNeedMD. The appointment of Mr. Loutzenhiser will be effective by April 15, 2016. The acquisition of Mediplex and the appointment of Mr ...


22.03.2016

InspireMD Announces Pricing of Public Offering

BOSTON, MA -- (Marketwired) -- 03/16/16 -- InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in embolic protection systems ("EPS"), today announced the pricing of an underwritten public offering of 1,900,000 shares of its common stock and warrants to purchase up to 950,000 shares of common stock (the "Public Offering"). The common stock will be sold at a price of $0.59 per share, and each purchaser will receive a warrant to purchas ...


16.03.2016

InspireMD Announces Private Placement to Certain Officers and Directors

BOSTON, MA -- (Marketwired) -- 03/16/16 -- InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in embolic protection systems ("EPS"), today announced a private placement (the "Private Placement") of up to 1,100,000 shares of its common stock and warrants to purchase up to 550,000 shares of common stock to certain of the Company''s officers and directors (the "Private Placement"). The common stock will be sold at a ...


16.03.2016

InspireMD Aligns Operations and Leadership Team, Appoints Isaac Blech as Vice Chairman of the Board

BOSTON, MA -- (Marketwired) -- 01/22/16 -- (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, announced today plans to align its operations and leadership with focus on its largest commercial markets in line with the continued execution of its carotid and neurovascular strategy which was launched in mid 2015.Key elements of the changes announced today include the recruitm ...


22.01.2016

InspireMD Receives EU Regulatory Approval for Additional Supplier of CGuard(TM) Delivery Catheters

BOSTON, MA -- (Marketwired) -- 12/02/15 -- (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, announced today receipt of a DEKRA medical device certification for the manufacture and commercialization of its CGuardTM delivery catheter, which now incorporates some design enhancements and a lower cost manufacturing structure to support the scale-up of operations. The certifi ...


02.12.2015

InspireMD Reports Financial Results for the Third Quarter Ended September 30, 2015

BOSTON, MA -- (Marketwired) -- 11/10/15 -- (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced its financial and operating results for the third quarter ended September 30, 2015.In its third full quarter of a strategic transition into the carotid and neuro interventional markets utilizing its proprietary MicroNet™ technology, key activities included the ann ...


10.11.2015

InspireMD to Report Financial Results for the Third Quarter Ended September 30, 2015 on Tuesday, November 10th

BOSTON, MA -- (Marketwired) -- 11/02/15 -- (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, announced today that it will release its full financial results for the third quarter ended September 30, 2015 on Tuesday, November 10th before the market open, followed by a conference call at 8:30 a.m. ET to review its financial results and business outlook.Participants should ...


02.11.2015

InspireMD Announces CGuardTM Approval in Argentina

BOSTON, MA -- (Marketwired) -- 10/19/15 -- InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, announced today that it has received regulatory approval to commercialize the CGuardTM Embolic Prevention System for the treatment of carotid artery disease in Argentina. The approval was granted by the Administracion Nacional de Medicamentos, Alimentos y Tecnologi ...


19.10.2015

InspireMD to Present at Dawson James Securities Growth Stock Conference

BOSTON, MA -- (Marketwired) -- 10/08/15 -- InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, announced today that Chief Executive Officer, Alan Milinazzo, will present at the Dawson James Securities Growth Stock Conference on October 15, 2015. The presentation will take place at 9:00 A.M. ET in the Wyndham Grand Hotel in Jupiter, Florida.InspireMD () seeks ...


08.10.2015

Update - InspireMD Announces CGuard(TM) Approval in Colombia

BOSTON, MA -- (Marketwired) -- 10/05/15 -- InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, announced today that it has received regulatory approval to commercialize the CGuard™ Embolic Prevention System for the treatment of carotid artery disease in Colombia. The approval was granted by the Instituto Nacional de Vigilancia de Medicamentos y Alimentos (IN ...


05.10.2015

InspireMD Announces CGuard(TM) Approval in Columbia

BOSTON, MA -- (Marketwired) -- 10/05/15 -- InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, announced today that it has received regulatory approval to commercialize the CGuard™ Embolic Prevention System for the treatment of carotid artery disease in Columbia. The approval was granted by the Instituto Nacional de Vigilancia de Medicamentos y Alimentos (IN ...


05.10.2015

InspireMD Announces One-for-Ten Reverse Stock Split

BOSTON, MA -- (Marketwired) -- 10/01/15 -- InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, announced today a one-for-ten reverse split of its common stock, effective as of 12:00 am Eastern Time on October 1, 2015. Beginning with the opening of trading on October 1, 2015, the Company''s common stock will trade on the NYSE MKT on a split adjusted ...


01.10.2015

InspireMD Announces Full Market Launch of CGuard(TM) Distributed by Penumbra at CIRSE Annual Congress

BOSTON, MA -- (Marketwired) -- 09/28/15 -- InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, announced today the full market launch of the CGuard™ Embolic Prevention System for the treatment of carotid artery disease by its strategic distribution partner, Penumbra, Inc. , at the CIRSE Annual Congress in Lisbon, Portugal. Penumbra, a global interventional t ...


28.09.2015

InspireMD Announces the Issuance of Two United States Patents

BOSTON, MA -- (Marketwired) -- 09/17/15 -- InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, announced today that the United States Patent & Trademark Office has issued two new patents to the Company on September 15th, U.S. Patent No. 9,132,261 entitled "In Vivo Filter Assembly" and U.S. Patent No. 9,132,003 entitled "Optimized Drug Elut ...


17.09.2015

InspireMD Announces Allowance of US Patent Claims

BOSTON, MA -- (Marketwired) -- 09/09/15 -- InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, announced today that the United States Patent & Trademark Office has allowed claims for its United States Patent Application, published as US2014/0309725 and entitled "Optimized Drug Eluting Stent Assembly." This patent covers any stent assembly with ...


09.09.2015

iNeedMD Holdings, Inc. Announces Its Q2 and First Half 2015 Results

NEW YORK, NY -- (Marketwired) -- 08/20/15 -- iNeedMD Holdings, Inc. (OTCQB: NEMD) ("iNeedMD" or the "Company") a medical diagnostic device development company, announces the filing of its quarterly report on Form 10-Q for the quarter ended June 30, 2015.iNeedMD became a reporting company in early 2015, and began commercializing product in the middle of the first quarter of the current calendar year. The Company''s flagship product, The EKG Glove™, is an FDA-cleared ...


20.08.2015

Jason Rupp Joins SEMDA as Executive Director

ATLANTA, GA -- (Marketwired) -- 02/10/15 -- Jason Rupp has joined the (SEMDA) as its first full-time Executive Director. Prior to joining SEMDA, Rupp spent 12 years in business development and marketing at the Advanced Medical Technology Association (AdvaMed) and the Biotechnology Industry Organization (BIO)."We are delighted to have someone with Jason''s depth of understanding of the medical device industry join SEMDA in the Executive Director position," said Tiffany Wilso ...


10.02.2015

Palm Beach Periodontist Uses Advanced Laser Technology to Treat Gum Disease

PALM BEACH GARDENS, FL -- (Marketwired) -- 11/20/13 -- Dr. Daniel Lauer, a in Palm Beach, is committed to offering the highest quality of dental care through comfortable, safe, and effective procedures. This dedication is especially apparent in his treatment options for gum disease.According to the Center for Disease Control and Prevention (CDC), 47.2% of adults in the U.S. have periodontal disease. While the traditional method of surgically treating can be unpleasant and inconvenient, Dr. La ...


20.11.2013

ChemDry Carpet Cleaning Franchise Benefits From Housing Market Warm Up

NASHVILLE, TN -- (Marketwired) -- 08/27/13 -- As soon as a potential home buyer walks through the front door of a home, the house is already making lasting impressions. Does the home look inviting? Are the rooms spacious? Does it look like somebody changed the oil of a 1974 Chevy Nova on the living room carpet? ChemDry cleans 10,000 homes a day -- enough to know that the last question isn't entirely a joke -- and has mastered the art of restoring a beat-up carpet to its previous glory, usi ...


27.08.2013

Palm Beach Periodontist Discusses Emdogain -- A New Method of Regenerating Gum Tissue That Can Eliminate the Need for Traditional Gum Tissue Grafting

PALM BEACH GARDENS, FL -- (Marketwired) -- 08/21/13 -- Dr. Daniel Lauer, a , has devoted a great deal of his education and career to helping his patients rejuvenate the health and appearance of their gums. At Precision Periodontics & Implant Dentistry, Dr. Lauer's private practice, his patients are offered treatment options that can restore both the form and function of the gums for a healthier smile and a renewed sense of self-confidence.According to a recent blog post titled ",& ...


21.08.2013

US-Russian Initiative in Life Science Cooperation

WASHINGTON, DC -- (Marketwired) -- 05/01/13 -- The Moscow Institute of Physics and Technology Biopharmaceutical cluster "Northern" (BPCN@MIPT), the Wisconsin Technology Innovation Initiative, Inc. (Wi2) (formed to support the University of Wisconsin School of Medicine and Public Health), and ChemDiv Research Institute announced the signing of a Memorandum of Understanding (MOU) to form a non-exclusive consortium developing innovative therapeutics aimed at improvement of human and anim ...


01.05.2013

DGAP-News: Linde AG: Linde to build natural gas terminal for Gassco AS in Emden (Germany)

DGAP-News: Linde AG / Key word(s): Contract Linde AG: Linde to build natural gas terminal for Gassco AS in Emden (Germany) 20.03.2013 / 08:30 --------------------------------------------------------------------- Linde to build natural gas terminal for Gassco AS in Emden (Germany) - Contract volume: Approximately EUR 260 million - Linde Engineering Dresden responsible for engineering, procurement and construction of terminal - Important distribution hub for Norwegian gas in German ...


20.03.2013

Ascendx Spine Wins Presenting Company SpotLight Award at SEMDA 2013 Conference

ATLANTA, GA -- (Marketwire) -- 03/07/13 -- In Room 222 at the SEMDA 2013 Conference, the hours rolled by, broken up into 15-minute increments. One by one, medical device executives stood in front of the crowd and described their companies, knowing that somewhere in the sea of investors' faces someone might be interested in their product or service.The 20 companies -- a record number -- selected to present at the annual Southeastern Medical Device Association (SEMDA) Conference may not know ...


07.03.2013

SEMDA 2013 Conference Breaks Prior Records

ATLANTA, GA -- (Marketwire) -- 02/28/13 -- The seventh annual conference produced by the Southeastern Medical Device Association (SEMDA) set a new record with more than 400 attendees, toppling the previous 2012 record of 300 participants. The SEMDA 2013 Conference was held February 19-20 at the Georgia Tech Global Learning Center in Atlanta.The SEMDA 2013 Conference also had a record number of participating companies, with 20 companies highlighting their technology and devices before a crowd th ...


28.02.2013

SEMDA Announces SpotLight Award Winners at 2013 Conference

ATLANTA, GA -- (Marketwire) -- 02/20/13 -- Cynthia L. Clark, President of ibiliti, and EndoChoice Inc. have received the 2013 SEMDA SpotLight Awards. Clark and Mark Gilreath, Founder and President of EndoChoice, accepted the awards. The awards were presented during the Gala Dinner at the highly successful 7th annual conference of the Southeastern Medical Device Association (SEMDA).SpotLight Awards recognize outstanding achievement in fostering the growth of the medical device community in the S ...


20.02.2013

Mir Imran, Prominent Healthcare Investor and Entrepreneur, to Speak at SEMDA 2013 Conference

ATLANTA, GA -- (Marketwire) -- 02/05/13 -- Mir Imran, a renowned healthcare investor and entrepreneur, will speak at the SEMDA 2013 Conference prior to leading a panel discussion with a group of distinguished and diverse investors.The seventh annual SEMDA Conference will be held on February 19-20, 2013, at the Georgia Tech Global Learning Center. Information and registration is available at . The Investor Panel will be on Wednesday, February 20th, beginning at 8:30 AM.The participants on the pa ...


06.02.2013

SEMDA Announces Record Number of Presenting Companies for 2013 Conference

ATLANTA, GA -- (Marketwire) -- 01/30/13 -- Selecting from a record number of applicants for the , the Southeastern Medical Device Association (SEMDA) has chosen 20 outstanding companies to present to investors. The companies include Series B, early revenue and emerging companies, all with compelling technologies and services that have the potential to bring value to the Southeast job market and benefit the global patient population.This is the first year that medical device data system (MDDS) c ...


30.01.2013

Universal Aviation Spain to Relocate Headquarters to Madrid-Barajas Airport (LEMD)

MADRID, SPAIN -- (Marketwire) -- 01/23/13 -- announced it is relocating its Madrid headquarters from Torrejon International Airport (LETO) to Madrid-Barajas International Airport (LEMD). The headquarters relocation was made based on the decision from Aeropuertos Españoles y Navegación Aérea (Aena) to close Torrejon Airport to general aviation aircraft effective Feb. 1, 2013."We are fully prepared for the transition of our headquarters, including all employees and equipment, from Torrejon ...


23.01.2013

TEDMED President Jon Ellenthal to Speak at SEMDA 2013 Conference

ATLANTA, GA -- (Marketwire) -- 01/21/13 -- Jonathan Ellenthal, a Partner and President of TEDMED, LLC, will speak at the SEMDA 2013 Conference. The seventh annual SEMDA Conference will be held on February 19-20, 2013, at the Georgia Tech Global Learning Center.Ellenthal joins a stellar line-up of speakers for the SEMDA 2013 Conference, including:Pat Mackin, SVP & President of the Cardiac Rhythm Disease Management Division, Medtronic Corporation;Mark Leahey, President & CEO Medical Devic ...


21.01.2013

EyeMD EMR Healthcare Systems & Advanced Data Systems Optimizing Ophthalmology Practice Automation

BONITA SPRINGS, FL and PARAMUS, NJ -- (Marketwire) -- 01/08/13 -- The EyeMD Electronic Medical Records system from (EEHS) and the ™ practice management system from (ADS) have been optimized to give ophthalmology practices an extraordinary return on investment, increased revenue, greater productivity, improved patient care and an excellent patient experience.A seamless, no cost bi-directional embedding of both systems brings the EyeMD EMR and the MedicsPremier PM together as a single, unified ...


08.01.2013

SEMDA Presenting Company Deadline Is January 9th for Medical Device and MDDS Companies Seeking Funding

ATLANTA, GA -- (Marketwire) -- 01/07/13 -- Time is running out for medical device and medical device data system (MDDS) companies seeking to present at the Southeastern Medical Device Association's 7th annual conference. The application deadline is this Wednesday, January 9, 2013."We are very excited about the quality of companies applying for this year's conference," said Angela Sinton, Chair of the Presenting Company Selection Committee. "As a result, we have added an ...


07.01.2013

MDMA Leader Mark Leahey to Speak at SEMDA 2013 Conference

ATLANTA, GA -- (Marketwire) -- 12/20/12 -- Mark B. Leahey, President and CEO for the Medical Device Manufacturers Association (MDMA), will speak at the SEMDA 2013 Conference. MDMA is a national trade association in Washington, DC, that represents hundreds of research-driven medical technology companies.The seventh annual SEMDA Conference will be held on February 19-20, 2013, at the Georgia Tech Global Learning Center. Applications for presenting companies and posters are being accepted through ...


20.12.2012

ChemDiv Receives Multiple Milestones in Major Drug Discovery Collaboration With Eli Lilly

SAN DIEGO, CA -- (Marketwire) -- 12/19/12 -- ChemDiv, Inc., a fully integrated drug discovery and development contract research organization with research facilities in San Diego, USA and Moscow, Russia, announced receipt of several milestones across three major therapeutic areas resulting from its collaboration with Eli Lilly. Financial details were not disclosed.Alex Kiselyov, Ph.D., President of ChemDiv commented: "Using our integrated drug discovery platforms, a team of chemists and bi ...


19.12.2012

Deadline Approaching for Medical Device and MDDS Companies Seeking Funding at SEMDA 2013

ATLANTA, GA -- (Marketwire) -- 12/13/12 -- There is less than one month remaining for medical device and medical device data system (MDDS) companies seeking funding to apply to present at the Southeastern Medical Device Association's (SEMDA) 7th annual conference. The Conference will be held February 19-20, 2013, at the Georgia Tech Global Learning Center in Atlanta."We already have a number of very strong companies that have applied to present, so we have increased the number of avai ...


13.12.2012

Dr. Jeffrey Shuren to Speak at SEMDA 2013 Conference

ATLANTA, GA -- (Marketwire) -- 11/28/12 -- Jeffrey Shuren, M.D., J.D., the Director of the Center for Devices and Radiological Health (CDRH) at the U.S. Food and Drug Administration (FDA), will speak at the SEMDA 2013 Conference.The seventh annual SEMDA Conference will be held on February 19-20, 2013, at the Georgia Tech Global Learning Center. Applications for presenting companies are currently being accepted, and sponsorships are available."The opportunity to hear Dr. Shuren speak, and t ...


28.11.2012

Coare Biotechnology and ChemDiv Establish Co-Marketing and Service Collaboration

SAN DIEGO, CA -- (Marketwire) -- 11/07/12 -- COARE Biotechnology (COARE) and ChemDiv, Inc. (ChemDiv) announced today the formation of a strategic alliance that will offer a fully integrated gene-to-clinic services aimed at development of therapeutic agents that selectively affect cancer stem cells (CSC).Under terms of this agreement, COARE contributes its pioneering research on the role of Doublecortin-like Kinase 1 (DCLK1) in proliferation and differentiation of CSC including relevant screenin ...


07.11.2012

Pat Mackin, President of Medtronic CRDM, to Keynote SEMDA 2013 Gala

ATLANTA, GA -- (Marketwire) -- 10/30/12 -- Pat Mackin, Senior Vice President and President of the Cardiac Rhythm Disease Management (CRDM) Division at Medtronic Corporation, will speak at the 2013 SEMDA Conference during the Gala Dinner.The seventh annual SEMDA Conference will be held on February 19-20, 2013, at the Georgia Tech Global Learning Center. Applications for presenting companies are currently being accepted, and sponsorships are available. The Gala Dinner will take place on February ...


30.10.2012

Seeking Medical Device or MDDS Funding? Apply Now for SEMDA 2013

ATLANTA, GA -- (Marketwire) -- 10/22/12 -- Medical device and medical device data system (MDDS) companies seeking funding are invited to apply to present at the Southeastern Medical Device Association's (SEMDA) 7th annual conference to be held February 19-20, 2013, at the Georgia Tech Global Learning Center.Brian Patrick, CEO of CoolCore Biomedical in Elgin, Texas, attended the 2012 Conference. "The SEMDA conference was very helpful to us because it attracted very large, acquisitive, ...


22.10.2012

SEMDA Announces Call for Presenting Companies

ATLANTA, GA -- (Marketwire) -- 09/12/12 -- Medical device and medical device data system (MDDS) companies seeking funding are invited to apply to present at the Southeastern Medical Device Association's (SEMDA) 7th annual conference to be held February 19-20, 2013, at the Georgia Tech Global Learning Center.Applications are now available at . There is no charge to apply. For companies selected (and that choose to present), the cost is just $750, which includes two conference admissions. Ea ...


12.09.2012

ChemDiv Research Institute Announces R&D Collaborations With Abbott in Russia

MOSCOW -- (Marketwire) -- 07/09/12 -- ChemDiv Research Institute (CDRI) at the ChemRar Hi-Tech Centre and Abbott, a global healthcare company, announced at the St. Petersburg International Economic Forum that they have signed an agreement to launch several R&D projects in Russia. This initiative is aimed to broaden therapeutic opportunities for the patients in Russia and to contribute to building an innovative pharmaceutical industry in Russia.The first collaboration between CDRI, the rese ...


09.07.2012

UCB and ChemDiv Research Institute Conclude First Phase of Discovery Chemistry Collaboration

SAN DIEGO, CA and BRUSSELS, BELGIUM and MOSCOW -- (Marketwire) -- 06/13/12 -- UCB and ChemDiv have successfully concluded the first phase of their 2011 collaborative discovery chemistry program executed with ChemDiv's Moscow subsidiary, the ChemDiv Research Institute.In the course of the collaboration, ChemDiv prepared hundreds of complex and highly targeted medicinal chemical scaffolds, building blocks and templates as part of a complete discovery chemistry solution. The partners' j ...


13.06.2012

Travelex Switzerland Launches New Website Offering Best Value Currency at the Click of a Button

ZURICH, SWITZERLAND -- (Marketwire) -- 06/07/12 -- , the world's leading currency exchange specialist has announced the launch of its new website in Switzerland.Designed to help customers save time and money before travelling abroad, allows customers to order from over 30 foreign currencies online, backed by Travelex' Best Price Guarantee. This ensures they get their travel money at Travelex's best rate, or they will be upgraded on collection.Ordering online is quick and easy an ...


07.06.2012

Travelex Switzerland Launches New Website Offering Best Value Currency at the Click of a Button

ZURICH, SWITZERLAND -- (Marketwire) -- 06/07/12 -- , the world's leading currency exchange specialist has announced the launch of its new website in Switzerland.Designed to help customers save time and money before travelling abroad, allows customers to order from over 30 foreign currencies online, backed by Travelex' Best Price Guarantee. This ensures they get their travel money at Travelex's best rate, or they will be upgraded on collection.Ordering online is quick and easy an ...


07.06.2012

EnerNOC Customers Win BBJ "Best Green Practices" Awards

BOSTON, MA -- (Marketwire) -- 05/15/12 -- (NASDAQ: ENOC), a leading provider of energy management applications for the smart grid, congratulates three of its customers that have been recognized by the Boston Business Journal (BBJ) for their excellence in innovative clean technology and energy management practices. EMD Millipore, an EnerNOC customer since 2007; National Grid, an EnerNOC customer since 2009; and the City of Boston, an EnerNOC customer since 2009, were honored at the BBJ's ...


15.05.2012

SEMDA Announces Date for 2013 Conference

ATLANTA, GA -- (Marketwire) -- 05/14/12 -- The Southeastern Medical Device Association's (SEMDA) 7th annual conference will take place on February 19-20, 2013. Recognized as the premier gathering for the Southeast medical device industry, the conference balances presentations by medical device companies to investors with educational programs, partnering and networking opportunities."The 2012 Conference was the most successful in the organization's history, and we are building on ...


14.05.2012

SEMDA SpotLight Awards Presented at Conference

ATLANTA, GA -- (Marketwire) -- 03/13/12 -- BD Technologies and H. Wayne Hodges, Executive Director of the Global Center for Medical Innovation (GCMI), will receive SpotLight Awards from the Southeastern Medical Device Association (SEMDA) as the 2012 Conference kicks off today. SEMDA's annual conference is recognized as the premier gathering for the Southeast medical device industry.The awards are one highlight of SEMDA's sixth annual conference, which has a record 300 people registere ...


13.03.2012

Duncan-Williams Shows Support for Medical Device Industry With Premier Sponsorship of SEMDA 2012 Conference

ATLANTA, GA and MEMPHIS, TN -- (Marketwire) -- 03/01/12 -- Duncan-Williams, Inc., a privately owned investment bank and broker-dealer headquartered in Memphis, TN, has signed on as premier sponsor of the annual SEMDA Conference. The sponsorship highlights the firm's healthcare expertise and demonstrates its ongoing commitment to support industry and community organizations.Leading Duncan-Williams' medical device industry focus is Ross DeDeyn, an Atlanta native with extensive experien ...


01.03.2012

SEMDA Announces Medical Device Companies That Will Present at the 2012 Conference

ATLANTA, GA -- (Marketwire) -- 02/24/12 -- The Southeastern Medical Device Association (SEMDA) has announced the companies that will present to attending investors at the . Presenting companies will have the opportunity to introduce their business plans and technology to venture capitalists, angel investors and corporations gathering from across the U.S.The sixth annual SEMDA Conference will be held on March 13-14, 2012, at the Georgia Tech Center for Global Learning. Recognized as the premier ...


24.02.2012

FDA Deputy Director for Medical Devices to Speak at SEMDA 2012 Conference

ATLANTA, GA -- (Marketwire) -- 02/08/12 -- William H. Maisel, MD, MPH, Chief Scientist and Deputy Center Director for Science at the U.S. 's (FDA) Center for Devices and Radiological Health (CDRH), will be a keynote speaker at the , it was announced today. Dr. Maisel is responsible for providing leadership in the development, implementation, execution, management and direction of the Center's broad national and international biomedical science programs.The sixth annual SEMDA Conferen ...


08.02.2012

SEMDA Conference to Include Free 1:1 Partnering Platform

ATLANTA, GA -- (Marketwire) -- 01/06/12 -- announced today that it will include 1:1 partnering at its 2012 Conference following a successful introduction in 2011. This valuable tool -- which allows attendees to maximize conference opportunities before, during and after the event -- is available at no additional charge for Conference attendees.Early registrants for the 2012 SEMDA Conference will benefit in two ways: not only can they save $100 on the cost of registration, but they will have ad ...


06.01.2012

ChemDiv, Inc. Enters Into Research and Collaboration Agreement With Janssen Pharmaceutica NV and Tibotec Pharmaceuticals

SAN DIEGO, CA and MOSCOW -- (Marketwire) -- 12/20/11 -- ChemDiv, Inc. (ChemDiv) announced today that it has entered into a multi-project research and collaboration agreement with Janssen Pharmaceutica NV (Janssen) and Tibotec Pharmaceuticals (Tibotec). Under the arrangement, ChemDiv will apply its integrated drug discovery expertise and technologies to identify novel small molecules against targets to be jointly agreed upon. For each research project, Janssen or Tibotec will fund certain R& ...


20.12.2011

SEMDA Announces Call for Presenting Companies

ATLANTA, GA -- (Marketwire) -- 12/14/11 -- Medical device companies seeking VC or angel funding are invited to apply to present at the Southeastern Medical Device Association's (SEMDA) 6th annual conference to be held March 13-14, 2012.Applications are now available at , and there is no charge to apply. Deadline for submissions is January 20, 2012. For companies selected that choose to present, the cost is just $750, which includes two conference admissions.Recognized as the premier gathe ...


14.12.2011

Jay S. Yadav, M.D., Named Chairman of SEMDA Board

ATLANTA, GA -- (Marketwire) -- 12/05/11 -- Jay S. Yadav, M.D., founder and CEO of , an Atlanta-based medical device company that has developed and is commercializing a proprietary wireless sensing and communication technology for the human body, has been elected Chairman of the Board of the (SEMDA).Dr. Yadav, an interventional cardiologist and a consulting cardiologist at the Piedmont Heart Institute, founded CardioMEMS in 2000 to develop new devices to improve the management of chronic cardi ...


05.12.2011



All members: 9 438
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 42


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.